Glue, Not Chains: Teaching AI to Degrade Amyloid-β the Hard Way
Glue sounds almost too gentle for Alzheimer’s disease. The usual business pitch for AI drug discovery prefers a louder vocabulary: acceleration, disruption, de-risking, platform advantage, and occasionally “revolution,” because apparently no investor memo can survive without one. This paper is more interesting when read against that noise. It does not show that AI has found an Alzheimer’s drug. It does not show that amyloid-β42 has been degraded in cells. It does not show brain delivery, toxicity control, animal efficacy, or clinical relevance. ...